• Users Online: 201
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2019  |  Volume : 5  |  Issue : 1  |  Page : 36

Authors' response: Letter to the editor on prevalence of metabolic syndrome in young patients with ST elevation myocardial infarction

Date of Submission09-Sep-2018
Date of Acceptance14-Sep-2018
Date of Web Publication21-Feb-2019

Correspondence Address:
Dr. Tugba Kemaloglu Oz
E5 Üzeri 23, Nisan Sok Merdivenköy No: 17, 34732, Kadiköy, Istanbul
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJCA.IJCA_38_18

Rights and Permissions

How to cite this article:
Oz TK, Özbilgin N, Sungur A, Bas EG, Zengin A, Gürol T, Soylu &, Dagdeviren B. Authors' response: Letter to the editor on prevalence of metabolic syndrome in young patients with ST elevation myocardial infarction . Int J Cardiovasc Acad 2019;5:36

How to cite this URL:
Oz TK, Özbilgin N, Sungur A, Bas EG, Zengin A, Gürol T, Soylu &, Dagdeviren B. Authors' response: Letter to the editor on prevalence of metabolic syndrome in young patients with ST elevation myocardial infarction . Int J Cardiovasc Acad [serial online] 2019 [cited 2019 Mar 23];5:36. Available from: http://www.ijcva.com/text.asp?2019/5/1/36/250805

We would like to thank Dr. Mahmoud Abdelnabi et al. for their valuable comments but according to our opinion, there is confusion about our study design. With regard to the remarks of Dr. Mahmoud Abdelnabi, it should be clear that:

  1. The main aim of the study was to determine the prevalence of metabolic syndrome (MS) in patients under 46 years of age who presented with ST elevation myocardial infarction and underwent primary percutaneous coronary intervention and especially this study did not focus on the morphology of coronary lesions
  2. The limitations of our study that we mentioned in the limitation part do not affect the prevalence of MS
  3. Over the last two decades, various organizations have proposed different definitions, using varying terminologies about MS. There are not just the International Diabetes Federation, the American Heart Association, and the World Health Organization (WHO) but also The European Group for Study of Insulin Resistance proposed a modification of the WHO definition
  4. Despite the large number of controversies regarding the nomenclature to be used, this conglomeration of various metabolic abnormalities in NCEP-ATP III criteria has been widely accepted as a screening tool for identifying subjects at high risk of cardiovascular disease and the aim of our study was not to compare these different definitions.


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article

 Article Access Statistics
    Viewed64    
    Printed3    
    Emailed0    
    PDF Downloaded14    
    Comments [Add]    

Recommend this journal